Showing 4361-4370 of 6036 results for "".
- BVI Expands IOL Capacity with New Facility in Belgiumhttps://modernod.com/news/bvi-expands-iol-capacity-with-new-facility-in-belgium/2481738/BVI has announced the opening of a new facility in Liège, Belgium that increases the company's IOL business capacity. BVI says the facility will unlock new growth opportunities while reinforcing the company’s environmental, social, and governance (ESG) leaders
- Visiox Pharma Licenses Glaucoma Drug Omlonti from Santenhttps://modernod.com/news/visiox-pharma-licenses-glaucoma-drug-omlonti-from-santen/2481736/Visiox Pharma announced it has entered into a definitive agreement with Santen Pharmaceutical to license glaucoma drug Omlonti (omidenepag isopropyl ophthalmic solution 0.002%). Specific financial terms of the deal were not disclosed. Omlonti was approved by th
- Harrow Acquires Santen’s Branded Ophthalmic Portfoliohttps://modernod.com/news/harrow-acquires-santens-branded-ophthalmic-portfolio/2481735/Harrow announced it is acquiring certain US and Canadian commercial rights to several branded ophthalmic products from Santen. According to an 8-K filing with the SEC, Harrow will make a one-time upfront payment of $8 million, with future near- and medium-term milestone
- Harrow Acquires US and Canadian Commercial Rights to Dry Eye Drug Vevye from Novaliqhttps://modernod.com/news/harrow-acquires-us-and-canadian-commercial-rights-to-vevye-cyclosporine-ophthalmic-solution-01-from-novaliq/2481734/Harrow has entered the prescription dry eye disease treatment business as it announced a deal to acquire the US and Canadian commercial rights to Vevye (cyclosporine ophthalmic solution 0.1%) from Novaliq. Under terms of the deal, Harrow will make an initi
- Medical Consulting Group and Corcoran Consulting Group Finalize Merger Agreementhttps://modernod.com/news/medical-consulting-group-and-corcoran-consulting-group-finalize-merger-agreement/2481723/Medical Consulting Group (MCG) and Corcoran Consulting Group (CCG) have finalized their merger that was announced in April. Financial terms of the deal were not disclosed. MCG and CCG stated they believe this merger will enhance the ophthalmic community by providing
- Tenpoint Therapeutics Launches with Goal of Reversing Vision Loss Through Engineered Cell-Based Therapeuticshttps://modernod.com/news/tenpoint-therapeutics-launches-with-goal-of-reversing-vision-loss-through-engineered-cell-based-therapeutics-and-in-vivo-reprogramming/2481720/Tenpoint Therapeutics announced its launch with a $70 million Series A financing to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions. Tenpoint was established based on the work of its scientific founders from Mo
- Allotex Secures Funding for Allogeneic Presbyopia Inlayshttps://modernod.com/news/allotex-secures-funding-for-allogeneic-presbyopia-inlays/2481717/Allotex and SpA announced the first close of its $30 million Series B financing to support the further development of its technology for the treatment of refractive errors. The investment was driven by 4-year data on presbyopia and hyperopia treatments, confirming significant impro
- Cognition Therapeutics Doses First Patient in MAGNIFY Study of Oral CT1812 for GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-dosing-of-first-patient-in-magnify-study-of-oral-ct1812-for-ga-secondary-to-dry-amd/2481714/Cognition Therapeutics announced that it has dosed the first participant in the phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The MAGNIFY study (COG2201,
- SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and Other Chronic Ophthalmic Diseaseshttps://modernod.com/news/spyglass-pharma-completes-90-million-series-c-financing-to-advance-novel-treatments-for-glaucoma-and-other-chronic-ophthalmic-diseases/2481711/SpyGlass Pharma announced the closing of $90 million in Series C financing to enable the company to conduct multiple US clinical trials of SpyGlass’ drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet n
- Heidelberg Engineering Names Hartmut Becker Head of Global Saleshttps://modernod.com/news/heidelberg-engineering-names-hartmut-becker-head-of-global-sales/2481710/Heidelberg Engineering has introduced Hartmut Becker as new Head of Global Sales, effective April 2023. In his new role, he will be leading the company’s sales and distribution activities across the group, and is responsible for supporting Heidelberg Engineering’s direct sub